Introduction

Inflammatory bowel disease (IBD) is a group of chronic immune system disorders characterized by remissions and relapses. Inflammatory bowel disease encompasses two related but distinct disorders: Crohn’s disease (CD) and ulcerative colitis (UC). CD is a chronic, idiopathic, transmural, patchy, inflammation of one or more segments of the gastrointestinal tract. UC is a chronic, idiopathic, diffuse mucosal inflammation of the colon [1, 2]. For patients with no clear features of either UC or CD, the term IBD-unclassified (IBD-U) could be employed.

The peak incidence of IBD is between the ages of 10 and 30 years. A recent study showed that 8–10% of all patients with IBD usually present in childhood and adolescence [3]. In Manitoba, we have recently shown that the sex- and age-adjusted incidence of pediatric CD has significantly increased from 1.2/100,000 in 1978 to 4.68/100,000 in 2007. For UC, the incidence has increased from 0.47/100,000 in 1978 to 1.64/100,000 in 2007. During the same time period, the prevalence of CD has significantly increased from 3.1 to 18.9/100,000 and from 0.7 to 12.7/100,000 for UC [4].

Scarcity of evidence-based knowledge in many aspects of IBD is a major challenge that could be related to several barriers. Those barriers include research funding difficulties, research-design related factors (such as randomized controlled studies versus observational studies), and physicians and health workers-related factors. For example, patients may have lower threshold to consent for research conducted by their treating physicians versus physicians and health care workers who are not involved in their care [5,6]. In a survey among North American Gastroenterologists examining barriers against clinical research, uncompensated research costs and a lack of specialized support were the most common barriers to research [6].

One major barrier to clinical research is the reduced willingness of patients to participate in clinical research [5,6]. Data on barriers for recruitment are limited, especially in the pediatric age group. The aim of this study was to determine the proportion of patients’ caregivers willing to participate in clinical research and examine possible barriers against clinical research in children with IBD from the perspective of patients and their caregivers.

Subjects and methods

Results

A total of 118 (98.3%) out of 120 caregivers of children (age < 18 years) with IBD who were approached completed the survey (Median age 14.46, IQR: 12.00–15.75 years, 60 boys, 61 CD). 110 (92%) participants were over the age of 7 years. Patients were followed for a median duration of 1.73 years (IQR 0.4–3.6 years). Patients’ demographics are summarized in Table 1. 14 (12%) participants had at least one sibling diagnosed with IBD.

Download:

• PPT
  PowerPoint slide
• PNG
  larger image
• TIFF
  original image

Table 1. Demographic characteristics of participants.

*As defined by clinical disease activity indices.

https://doi.org/10.1371/journal.pone.0206965.t001

One hundred and four (88.2%) caregivers were “Definitely” or “Probably” willing to participate in clinical research while 14 (11.8%) were “Neutral” or”Probably” unwilling to participate (P<0.001). Responses are summarized in Table 2.

Download:

• PPT
  PowerPoint slide
• PNG
  larger image
• TIFF
  original image

Table 2. Willingness to participate in clinical research of children with IBD.

https://doi.org/10.1371/journal.pone.0206965.t002

Seventy four (62.7%) participants previously participated in at least one study and 21 (17.8%) previously declined participation in one or more research studies. The majority of participants [71 (60.2%)] patients thought that a monthly clinic visit would not make any difference in encouraging participation in clinical research.

Ninety participants (76.3%) agreed to participate in studies that include obtaining “two small” blood samples, 88 (74.6%) agreed to give one urine sample, and 71 (60.2%) agreed to give a stool sample. On the other hand, 84 (71.2%) patients would decline participating in studies that include obtaining endoscopy biopsy samples.

Fifty eight (49.2%) participants thought that money ($100) would encourage participation in clinical research (P = 0.8).

Patients were less likely to participate in clinical research if they had longer disease duration (P = 0.019), or were in clinical relapse at the time of participation (P = 0.03). Patients were also less likely to participate if they were asked to provide tissue biopsy samples (P = 0.05). Other biological samples such as blood samples (P = 0.7), urine (P = 0.1) or stool (P = 0.8) samples did not seems to make any difference on patients’ willingness to participate. Nature of research studies such as randomized controlled studies (P = 0.2) or open labelled studies (P = 0.3), family history of IBD (P = 0.4), parents’ education (P = 0.8), family income of over $ 31,000.00 per annum (P = 0.5), money incentive (P = 0.8), and medications, such as immunosuppressive or biological medications, at the time of the survey did not have any significant effect on willingness to participate.

Discussion

The variety of barriers against recruitment for clinical research studies in children with inflammatory bowel disease (IBD) needs to be identified and examined in order to work towards resolving these barriers and encourage recruitment. In our study, the majority of children and their caregivers were willing to participate in clinical research, especially if they had shorter disease duration or were in clinical remission at the time of the survey.

Studies examining barriers to recruitment in children with chronic diseases including IBD are scarce. In a cross-sectional study, Hoberman and colleagues surveyed parents previously asked to provide consent for their child’s participation in the trial about factors that influenced their decision. Having graduated from college and private health insurance were associated with lower likelihood of providing consent. Parents who perceived the study as having a low degree of risk, resulting in greater benefit to their child and other children, causing no or minor interference with the standard care or who perceived the researcher as professional were significantly more likely to consent to participate [8]. In our study, parents’ education did not seem to have a major association with willingness to participate in clinical research. A major limitation of the study by Hoberman et al was the low participation rate of the survey as only 44% of those who were invited to participate actually answered the survey questions.

In comparison to our study, invasive procedures such as colonoscopies or sigmoidoscopies did not have a positive influence on willingness to participate in research studies for adults with IBD in a study that surveyed 200 patients with IBD [9]. Other factors that interfered with willingness to participate included the need for frequent physician visits and the blinding design. Male gender, compensation, and active disease at the time of survey were associated with higher willingness to participate [9]. A telephone interview with patients with systemic lupus erythematosus who accepted or refused to participate in clinical trials indicated the presence of several factors that affected the decision-making process of participation. Those factors included health status at the time of participation, study design, physician involvement, altruism, personal benefit and incentives. Good health status, encouragement from one’s physician and personal desire to learn and contribute stimulated participation [10]. The gender of participants is another potential factor that may affect willingness to participate in clinical research. Ding et al. explored this factor in a multi-center study to examine the willingness of patients with cardiovascular disease to participate in clinical trials. Women were less willing to participate as they perceived greater risks of chronic disease-related harm [11]. We did not encounter the same finding in our study as parents’ views for their children to participate in clinical research may be different from their willingness for their own participation i.e. Parents may have a lower threshold to participate in clinical research as they feel less anxious compared to their feelings towards their children’s participation.

Although ethically controversial, paying participants as a motivator for participation in clinical research was explored among other factors in a study by Halpern et al [12]. Willingness to participate decreased by lower payment level, higher risks of adverse events, and higher risks for being assigned to placebo. Higher payments did not alter participants’ reaction to the examined risk factors such as adverse events, suggesting that higher payments did not alter participants’ perception of risks. Interestingly, in this study, wealthier participants were more likely to state that payment was important in their participation decision [12]. In our study, paying money as an incentive for participation did not seem to be associated with a higher willingness to participate.

Our study is unique and novel. This is the first study examining barriers to clinical research among parents and children with IBD. In addition, the study has an excellent response rate to the invitation to complete the survey reaching up to 98.3%. This may reflect a high level of motivation of both patients’ caregivers and our research team.

On the other hand, our study is limited by using a non-validated survey tool. However, there is no validated tool in this context.

Although the majority of our participants were willing to participate, actual consent for participation in clinical research may vary. Nonetheless, our study highlights some factors and difficulties that should be taken into consideration when researchers plan for studies for children with IBD. Disease relapse may not be the best time for approaching participants. Researchers should be aware that they may not be able to obtain endoscopy biopsy and stool research samples in up to 70% and 40% of children with IBD respectively. This could be proven valuable in sample size calculation. On the other hand, patients seem to be willing to donate blood samples over stool samples. This might be explained by the easiness to collect blood over stools and the fact that adolescents seem to feel disgusted by the process of stool collection.

Conclusions

The majority of caregivers of children with IBD, especially those with Crohn’s disease, are willing to participate in clinical research. Patients are less likely to consent for clinical research if they have longer disease duration and were approached at the time of clinical relapse. Future research studies examining strategies to change the attitude of patients’ caregivers towards certain barriers such as collection of tissue sample biopsies are warranted.

Supporting information